ライフサイエンスコーパス: non-alcoholic fatty liver disease

1 tabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease.

2 ovel therapeutic target for diseases such as non-alcoholic fatty liver disease.

3 potential to treat both atherosclerosis and non-alcoholic fatty liver disease.

4 hepatitis C and emergence of cirrhosis from non-alcoholic fatty liver disease.

5 present a novel avenue for the treatment of non-alcoholic fatty liver disease.

6 ch probably increasing the susceptibility to non-alcoholic fatty liver disease.

7 and concomitant protection from diet-induced non-alcoholic fatty liver disease.

8 and hepatocyte lipoapoptosis are features of non-alcoholic fatty liver disease.

9 f metabolic conditions including obesity and non-alcoholic fatty liver disease.

10 ased atherosclerosis, increased obesity, and non-alcoholic fatty liver disease.

11 ages might be a novel therapeutic target for non-alcoholic fatty liver disease.

12 t CaMKK2 function confers protection against non-alcoholic fatty liver disease.

13 been implicated in fatty liver formation in non-alcoholic fatty liver disease.

14 BP-regulated de novo lipogenesis involved in non-alcoholic fatty liver disease.

15 provide unique targets for the treatment of non-alcoholic fatty liver disease.

16 lly therapeutic role of PHLPP2 activators in non-alcoholic fatty liver disease.

17 and metabolic outcomes in participants with non-alcoholic fatty liver disease.

18 function in other hepatic diseases, such as non-alcoholic fatty liver disease.

19 have liver fibrosis, mostly associated with non-alcoholic fatty liver disease.

20 n that causes insulin-resistant diabetes and non-alcoholic fatty liver disease.

21 eatures of the metabolic syndrome, including non-alcoholic fatty liver disease.

22 be a promising approach for the treatment of non-alcoholic fatty liver disease.

23 ecies (ROS) contribute to the development of non-alcoholic fatty liver disease.

24 type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

25 etes, atherosclerotic vascular diseases, and non-alcoholic fatty liver disease.

26 nisms responsible for disease progression in non-alcoholic fatty liver disease.

27 erglycaemic, hyperinsulinaemic and developed non-alcoholic fatty liver disease.

28 ity, adipocyte hypertrophy, and present with non-alcoholic fatty liver disease; 3) DKO mice demonstra

29 red liver histology defined as a decrease in non-alcoholic fatty liver disease activity score by at l

30 ntent), as well as elevated inflammation and non-alcoholic fatty liver disease activity scores, and h

31 in both the metabolic syndrome accompanying non-alcoholic fatty liver disease and cellular apoptosis

32 Increases in non-alcoholic fatty liver disease and drug-induced hepat

33 Non-alcoholic fatty liver disease and early fibrosis wer

34 Non-alcoholic fatty liver disease and its downstream seq

35 wed a substantial overlap with biomarkers of non-alcoholic fatty liver disease and its progression to

36 ACT: Low aerobic capacity increases risk for non-alcoholic fatty liver disease and liver-related dise

37 plasma lipoprotein metabolism, alcoholic and non-alcoholic fatty liver disease and myocardial infarct

38 ht to be of relevance for the development of non-alcoholic fatty liver disease and obesity.

39 ute to various metabolic diseases, including non-alcoholic fatty liver disease and type 2 diabetes.

40 ism could alleviate the related epidemics of non-alcoholic fatty liver disease and type 2 diabetes.

41 y for treating inflammatory diseases such as non-alcoholic fatty liver disease and type 2 diabetes.

42 Ninety four eligible patients who have non-alcoholic fatty liver disease and who are insulin re

43 besity, insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, and cancer.

44 bowel syndrome, and metabolic (i.e. obesity, non-alcoholic fatty liver disease, and diabetes) and neu

45 mote progression of alcoholic liver disease, non-alcoholic fatty liver disease, and non-alcoholic ste

46 complications such as insulin resistance and non-alcoholic fatty liver disease are reaching epidemic

47 , GLUT2 may contribute to the development of non-alcoholic fatty liver disease by facilitating the up

48 ns or rodents to high-calorie diets promotes non-alcoholic fatty liver disease, characterized by neut

49 Participants with non-alcoholic fatty liver disease (defined as (1)H magne

50 sis of several metabolic diseases, including non-alcoholic fatty liver disease, diabetes mellitus, an

51 with risk factors of liver disease, such as non-alcoholic fatty liver disease, hazardous alcohol use

52 ein 5 in vivo prior to or after establishing non-alcoholic fatty liver disease in mice.

53 ivity, and prevents metabolic stress-induced non-alcoholic fatty liver disease in mice.

54 tic fat accumulation and provides a model of non-alcoholic fatty liver disease in which to study the

55 at diet (HFD) consumption is associated with non-alcoholic fatty liver disease, increased apoptosis,

56 Non-alcoholic fatty liver disease is a serious health pr

57 mmation and fibrosis in humans and mice with non-alcoholic fatty liver disease is accompanied by accu

58 Non-alcoholic fatty liver disease is associated with hep

59 Non-alcoholic fatty liver disease is associated with mul

60 Steatohepatitis due to non-alcoholic fatty liver disease is developing into a n

61 The prevalence of non-alcoholic fatty liver disease is increasing worldwid

62 Non-alcoholic fatty liver disease is the most rapidly gr

63 HSCs and in a human cohort of subjects with non-alcoholic fatty liver disease (N = 146).

64 tokine fetuin-A may impair renal function in non alcoholic fatty liver disease (NAFLD) by altering in

65 sis models (n = 3-5) and in human samples of non-alcoholic fatty liver disease (NAFLD) (n = 72-135).

66 Non-alcoholic fatty liver disease (NAFLD) affects a larg

67 Non-alcoholic fatty liver disease (NAFLD) and cardiovasc

68 the gut microbiota in choline deficiency in non-alcoholic fatty liver disease (NAFLD) and insulin re

69 Non-alcoholic fatty liver disease (NAFLD) and its more s

70 e similar to those observed in patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoho

71 he serum XPO4 pattern in a broad spectrum of non-alcoholic fatty liver disease (NAFLD) cases.

72 Non-alcoholic fatty liver disease (NAFLD) characterizes

73 afer and more effective hepatitis C therapy, non-alcoholic fatty liver disease (NAFLD) could soon eme

74 The approach was developed on a non-alcoholic fatty liver disease (NAFLD) data set.

75 e a non-invasive fibrosis scoring system for non-alcoholic fatty liver disease (NAFLD) derived from r

76 Non-alcoholic fatty liver disease (NAFLD) has been recen

77 on liver function in bariatric patients with non-alcoholic fatty liver disease (NAFLD) in a randomize

78 Recent studies have raised the concept that non-alcoholic fatty liver disease (NAFLD) in adults is d

79 Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients wi

80 The incidence of non-alcoholic fatty liver disease (NAFLD) increases with

81 Non-alcoholic fatty liver disease (NAFLD) is a common me

82 Non-alcoholic fatty liver disease (NAFLD) is a major ris

83 Non-alcoholic fatty liver disease (NAFLD) is an increasi

84 Non-alcoholic fatty liver disease (NAFLD) is becoming th

85 Non-alcoholic fatty liver disease (NAFLD) is defined as

86 of the gut microbiome in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is emerging.

87 Non-alcoholic fatty liver disease (NAFLD) is one of the

88 Non-alcoholic fatty liver disease (NAFLD) is one of the

89 Non-alcoholic fatty liver disease (NAFLD) is one of the

90 The prevailing theory in non-alcoholic fatty liver disease (NAFLD) is the "two-hi

91 Non-alcoholic fatty liver disease (NAFLD) is the hepatic

92 Non-alcoholic fatty liver disease (NAFLD) is the most co

93 Non-alcoholic fatty liver disease (NAFLD) is the most co

94 ociated genes in the gastric tissue of obese non-alcoholic fatty liver disease (NAFLD) patients.

95 Non-alcoholic fatty liver disease (NAFLD) represents a s

96 The process initiates with non-alcoholic fatty liver disease (NAFLD) that progresse

97 Increasing evidence connects non-alcoholic fatty liver disease (NAFLD) to CKD.

98 tors FXR and CAR in disease progression from non-alcoholic fatty liver disease (NAFLD) to HCC.

99 There is no licensed treatment for non-alcoholic fatty liver disease (NAFLD), a condition t

100 -2006), overweight children with and without non-alcoholic fatty liver disease (NAFLD), and children

101 t only affected by the metabolic syndrome as non-alcoholic fatty liver disease (NAFLD), but may contr

102 yndrome (PCOS) is frequently associated with non-alcoholic fatty liver disease (NAFLD), but the mecha

103 d autophagy is associated with steatosis and non-alcoholic fatty liver disease (NAFLD), however the m

104 In non-alcoholic fatty liver disease (NAFLD), lipid build-u

105 blood spot testing-is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD), non-alcoholic

106 with chronic hepatitis B (CHB) and 488 with non-alcoholic fatty liver disease (NAFLD), those with rs

107 biting recessive male-specific lethality and non-alcoholic fatty liver disease (NAFLD), which coincid

108 Non-alcoholic fatty liver disease (NAFLD), which include

109 caemic control in pre-diabetic patients with non-alcoholic fatty liver disease (NAFLD).

110 d increased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

111 protein F (APO-F), a potential biomarker for non-alcoholic fatty liver disease (NAFLD).

112 chanisms differ in drug induced (DIS) and/or non-alcoholic fatty liver disease (NAFLD).

113 d increased oxidative damage are features of non-alcoholic fatty liver disease (NAFLD).

114 ged as a potential plasma marker to diagnose non-alcoholic fatty liver disease (NAFLD).

115 e (BBR) is beneficial for obesity-associated non-alcoholic fatty liver disease (NAFLD).

116 efficacy of sevelamer in treating mice with non-alcoholic fatty liver disease (NAFLD).

117 Visceral obesity is often accompanied by non-alcoholic fatty liver disease (NAFLD).

118 y and progression of liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatoh

119 The progressive non-alcoholic fatty liver disease observed in the LCR ra

120 was also able to reverse already established non-alcoholic fatty liver disease, resulting in signific

121 c steatosis both in an inbred mouse model of non-alcoholic fatty liver disease (SJL/J) and in a human

122 Non-alcoholic fatty liver disease, the most prevalent li

123 factors contributing to the pathogenesis of non-alcoholic fatty liver disease, we examined liver ste

124 type 2 diabetes mellitus has been linked to non-alcoholic fatty liver disease, which can progress to